MannKind Beset With Afrezza Clinical Trial Fraud Allegations

摘要

Less than two months before the FDA makes a decision on its inhaled insulin Afrezza, MannKind is facing allegations of clinical trial improprieties from a former employee.rnJohn Arditi, MannKind's former senior director of regulatory affairs, filed a lawsuit in a New Jersey state court against MannKind and several executives Sept. 16 alleging he was fired in retaliation for his insistence that MannKind alert the FDA to improprieties in Afrezza's clinical trials. The suit was disclosed in a recently filed company quarterly SEC filing.